Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results

Thursday March 1st, 2018

Time of Event: 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time

Telephone Dial in:  toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally
Conference ID: 8962269

For more information about this event, please see the press release.

Read more

Kindred Biosciences to Announce Fourth Quarter and Year-End 2017 Financial Results

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Thursday, March 1, 2018

San Francisco, CA (February 15, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its fourth quarter and year-end 2017 financial results on March 1, 2018 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day.

Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 8962269.

The call will also be webcast live at https://edge.media-server.com/m6/p/w3hyojgg.

A replay will also be available at that link for 30 days.

About Kindred Biosciences

Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

 

Contact

Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904

Event: Bank of America Merrill Lynch Animal Health Summit (February 26, 2018)

February 26, 2018

Time of Event: 10:30 a.m. Pacific Time
Event Location: New York City
Company Attendee:  Richard Chin, MD, Founder and CEO

For more information about this event, please see the press release. Read more

Kindred Biosciences to Participate in the Bank of America Merrill Lynch Animal Health Summit

SAN FRANCISCO, Feb. 13, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the Bank of America Merrill Lynch Animal Health Summit on February 26, 2018 in New York City.

Richard Chin, M.D., President and Chief Executive Officer, will participate in a panel discussion entitled, “Innovation in Companion Animal Therapeutics.” The event will also feature one-on-one meetings at which investors will have the opportunity to meet with Dr. Chin to discuss KindredBio’s key therapeutic programs in development and upcoming milestones.

About Kindred Biosciences

Kindred Biosciences is a pre-commercialization stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.

For more information or to download the corporate presentation, visit www.KindredBio.com/LearnMore. Stay connected with KindredBio on Facebook at www.Facebook.com/KindredBio.

 

Contact

Russell Radefeld
KindredBio
russell.radefeld@kindredbio.com
(650) 701-7904